Granted Patent B2

US 12,269,856 · App. 18/477,490 · Granted Apr 8, 2025

Inventors: Mark Leslie Smythe (Bardon, AU); Gregory Thomas Bourne (Brisbane, AU); Simone Vink (Taringa, AU); Brian Troy Frederick (Ben Lomand, CA); Praveen Madala (Brisbane, AU); Anne Pernille Tofteng Shelton (Valby, DK); Jacob Ulrik Fog (Bagsvaerd, DK)

Assignee: Protagonist Therapeutics, Inc.

C07K14/575A61K38/00

Abstract

Claims (21)

1. A method of treating a disease of iron metabolism in a subject in need thereof comprising administering to said subject a peptide comprising the sequence

(SEQ ID NO: 241)

Isovaleric acid-DTHFPCI(K(isoGlu-Palm))FEPRSKGCK-

NH 2

or a pharmaceutically acceptable salt thereof, and

wherein the peptide of SEQ ID NO: 241 comprises a disulfide bond between two cysteine residues;

wherein the disease of iron metabolism is hereditary hemochromatosis, iron hemochromatosis, HFE mutation hemochromatosis, ferroportin mutation hemochromatosis, transferrin receptor 2 mutation hemochromatosis, hemojuvelin mutation hemochromatosis, hepcidin mutation hemochromatosis, juvenile hemochromatosis, neonatal hemochromatosis, hepcidin deficiency, transfusional iron overload, thalassemia, thalassemia intermedia , β-thalassemia, or alpha thalassemia.

2. The method of claim 1 , wherein the peptide of SEQ ID NO: 241 comprises the structure

3. The method of claim 1 , wherein the subject is a mammal.

4. The method of claim 3 , wherein the mammal is a human.

5. The method of claim 1 , comprising administering the peptide in a pharmaceutical formulation comprising a pharmaceutically acceptable carrier.

6. The method of claim 5 , wherein the pharmaceutical formulation is for oral, intravitreal, rectal, vaginal, nasal, topical, enteral or parenteral-administration.

7. The method of claim 5 , wherein the pharmaceutical formulation is for oral administration.

8. The method of claim 5 , wherein the pharmaceutical formulation is for subcutaneous administration.

9. The method of claim 5 , wherein the pharmaceutical formulation is a capsule, cachet, or tablet.

10. The method of claim 5 , wherein the pharmaceutical formulation is a single-dose injectable.

11. The method of claim 1 , the method further comprising administering the peptide or the pharmaceutically acceptable salt thereof in a dosage of about 0.0001 to about 100 mg/kg body weight per day.

12. The method of claim 1 , the method further comprising administering the peptide or the pharmaceutically acceptable salt thereof in a dosage of about 0.001 to about 10 mg/kg body weight per day.

13. The method of claim 1 , the method further comprising administering the peptide or the pharmaceutically acceptable salt thereof in a dosage of about 0.01 to about 1 mg/kg body weight per day.

14. The method of claim 13 , the method further comprising administering the peptide or the pharmaceutically acceptable salt thereof once daily, twice daily, once every two, three, four, five or six days, once or twice weekly, or once or twice monthly.

15. The method of claim 5 , wherein the pharmaceutical formulation is for intramuscular, intravenous, intradermal, or transdermal administration.

Assignments (3)

Continuity (11)

References Cited (352)